Shanghai Henlius Biotech
3 clinical trials · 3 recruiting · INDUSTRY
Trials by Shanghai Henlius Biotech
RECRUITINGPhase 1NCT07160335
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in...
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17...
Sponsor: Shanghai Henlius BiotechEnrolling: 17420 locations
Non-small Cell Lung CancerMelanomaRenal Cell Carcinoma
RECRUITINGPhase 2NCT06349980
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or...
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1...
Sponsor: Shanghai Henlius BiotechEnrolling: 1171 location
Carcinoma, Hepatocellular
RECRUITINGPhase 2NCT06769113
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to...
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic...
Sponsor: Shanghai Henlius BiotechEnrolling: 721 location
Esophageal Cancer